Chapter 3.II: XEVPRM user guidance of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Submitted by Anonymous (not verified) on 22 July 2024 - 8:48

Chapter 3.II: XEVPRM user guidance of the Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the EMA

Opinion/decision on a Paediatric investigation plan (PIP): Spikevax (previously COVID-19 Vaccine Moderna), elasomeran,imelsomeram,davesomeran, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious d

Submitted by Anonymous (not verified) on 19 July 2024 - 15:53

Opinion/decision on a Paediatric investigation plan (PIP): Spikevax (previously COVID-19 Vaccine Moderna), elasomeran,imelsomeram,davesomeran, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases;Vaccines, PIP number: P/0152/2023

Opinion/decision on a Paediatric investigation plan (PIP): Vydura, Rimegepant, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0142/2023

Submitted by Anonymous (not verified) on 19 July 2024 - 15:38

Opinion/decision on a Paediatric investigation plan (PIP): Vydura, Rimegepant, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neurology, PIP number: P/0142/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness